Grace Therapeutics Inc (GRCE) Stock Price, Quote & News

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology

Sector: Healthcare

Phone: 609-322-1602

Website: www.gracetx.com

Address:

103 Carnegie Center, Suite 300, Princeton, United States

alexpitti Sep. 5 at 9:51 PM

I should have a large position in UNDISCLOSED and not bother with $AUTL, but I have this obsession with Autolus. I know this stock shouldn't be this low. I just know it! It must reverse sometime soon. Also I'm way more bullish on $DCTH than $ABEO, but I don't like selling stocks I'm very bullish on just to slightly alter allocations (bad for taxes & stress). Delcath is actually my top idea, then Stereotaxis, then, UNDISCLOSED, then Abeona, then Autolus, and finally Grace (no position). $GRCE

3 · Reply

Greenpa Sep. 5 at 7:44 PM

$GRCE Hesitant to recommend an AI piece, but below NVIDIAmillionare post is quite informative. It provides details on two other drugs in pipeline that I did not know.

1 · Reply

NVDAMillionaire Sep. 5 at 3:35 PM

$GRCE Brilliant piece that captures GRCE's situation perfectly. So if you want to update your understanding of GRCE or get to know GRCE better, this is essential reading. https://beyondspx.com/quote/GRCE/grace-therapeutics-injecting-innovation-into-rare-disease-treatment-with-gtx-104-s-market-ascent-nasdaq-grce#analysis

0 · Reply

Greenpa Sep. 5 at 11:15 AM

$GRCE Nothing is certain in life and this is technically a binary bet, but it is hard to imagine how the FDA won’t approve a drug where trial shows the new formulation is safer and more effective. I can wait 8 months for the payoff, but in theory smart money should push price up to reflect odds sooner than that.

0 · Reply

BB_88_ Sep. 4 at 8:31 PM

$GRCE she will rise soon

0 · Reply

alexpitti Sep. 2 at 1:02 AM

$GRCE operation keep the stock above $3.003 commences

0 · Reply

Manonfire8 Aug. 27 at 7:23 PM

$GRCE this looks like a sell to the warrant price of 3.003. Probably uptrend forms after this

0 · Reply

alexpitti Aug. 27 at 5:40 PM

$GRCE ok sorry approval date is april 23rd. huge news

0 · Reply

shade00tree Aug. 27 at 5:27 PM

$GRCE

0 · Reply

Manonfire8 Aug. 27 at 4:29 PM

$GRCE I closed my $ESPR position to load into this 😒 wtf

1 · Reply

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 12 days ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 12, 2025, 8:00 AM EDT - 27 days ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Jun 25, 2025, 8:00 AM EDT - 2 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 23, 2025, 8:00 AM EDT - 2 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 13, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Apr 9, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 6 months ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Feb 25, 2025, 8:00 AM EST - 6 months ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 7 months ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 10, 2025, 12:05 PM EST - 7 months ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 8:05 AM EST - 7 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 7 months ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 8 months ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Oct 25, 2024, 8:00 AM EDT - 11 months ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 1, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 1 year ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 1 year ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

May 17, 2023, 9:00 AM EDT - 2 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 8, 2023, 7:00 AM EDT - 2 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Apr 4, 2023, 8:01 AM EDT - 2 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Mar 30, 2023, 8:30 AM EDT - 2 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 8, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Feb 28, 2023, 1:00 PM EST - 2 years ago

Acasti Pharma Recognizes Rare Disease Day

Feb 14, 2023, 3:53 PM EST - 2 years ago

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

Feb 14, 2023, 7:00 AM EST - 2 years ago

Acasti Pharma Reports Third Quarter 2023 Operational Results

Feb 7, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Jan 25, 2023, 9:00 AM EST - 2 years ago

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Jan 24, 2023, 4:15 PM EST - 2 years ago

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

Jan 17, 2023, 8:45 AM EST - 2 years ago

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

alexpitti Sep. 5 at 9:51 PM

3 · Reply

Greenpa Sep. 5 at 7:44 PM

$GRCE Hesitant to recommend an AI piece, but below NVIDIAmillionare post is quite informative. It provides details on two other drugs in pipeline that I did not know.

1 · Reply

NVDAMillionaire Sep. 5 at 3:35 PM

0 · Reply

Greenpa Sep. 5 at 11:15 AM

0 · Reply

BB_88_ Sep. 4 at 8:31 PM

$GRCE she will rise soon

0 · Reply

alexpitti Sep. 2 at 1:02 AM

$GRCE operation keep the stock above $3.003 commences

0 · Reply

Manonfire8 Aug. 27 at 7:23 PM

$GRCE this looks like a sell to the warrant price of 3.003. Probably uptrend forms after this

0 · Reply

alexpitti Aug. 27 at 5:40 PM

$GRCE ok sorry approval date is april 23rd. huge news

0 · Reply

shade00tree Aug. 27 at 5:27 PM

$GRCE

0 · Reply

Manonfire8 Aug. 27 at 4:29 PM

$GRCE I closed my $ESPR position to load into this 😒 wtf

1 · Reply

bdetweiler Aug. 27 at 2:57 PM

$GRCE Ok I hate this stock.

0 · Reply

nevercool Aug. 27 at 2:43 PM

$GRCE should be lifting... Still

0 · Reply

JujuInvestor2013 Aug. 27 at 12:34 PM

$GRCE very good news for grace… let’s see how the market reacts 😉🙏🚀 https://www.gurufocus.com/news/3081590/grace-therapeutics-announces-us-food-and-drug-administration-acceptance-for-review-of-new-drug-application-for-gtx104-grce-stock-news

1 · Reply

EagleShares Aug. 27 at 12:29 PM

$GRCE get to digging everybody, this is working out great. News are 👌

0 · Reply

TA_Kongen Aug. 27 at 12:11 PM

$GRCE Volume watch. Warrants active now due to news. 3.39 exercise from Private Placement.

1 · Reply

Greenpa Aug. 27 at 12:11 PM

$GRCE Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 April 23,2026 PDUFA date. I believe that is accelerated beyond normal 10 months. Looks VERY promising.

0 · Reply

Stratyx Aug. 26 at 11:38 PM

$GRCE NDA acceptance is big news because it validates that the filing is solid, driving investor interest. Especially considering it leads directly to an FDA approval

1 · Reply

alexpitti Aug. 26 at 9:44 PM

I don't see NDA acceptance as bid news. An approval would be big news. That's coming in early July $GRCE

0 · Reply

Stratyx Aug. 26 at 1:57 PM

$GRCE this has gotta be one of the most boring chat boards for big news about to drop lol

2 · Reply

JujuInvestor2013 Aug. 26 at 12:30 PM

$GRCE today is maybe the DAY with nda acceptance 😊

1 · Reply

alexpitti Aug. 23 at 2:55 AM

my top 3 watch list stocks are $AUTL, $SI, and $GRCE. after the recession, i will reconsider $VFC

1 · Reply

alexpitti Aug. 21 at 3:55 PM

$GRCE i expect nda acceptance early next week

0 · Reply

Market Cap	44.25M
Revenue (ttm)	0.00
Net Income (ttm)	-9.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	257,000
Avg Vol	79,756
Day's Range	N/A - N/A
Shares Out	13.83M
Stochastic %K	60%
Beta	1.06
Analysts	Strong Sell
Price Target	$11.83